GHRP-2 Research Overview (also known as Growth Hormone Releasing Peptide-2, GHRP-2 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2))
A synthetic hexapeptide GH secretagogue (GHS-R1a agonist) with published human pharmacokinetic data, pediatric short-stature trials, and adult studies on GH pulsatility, appetite stimulation, and anti-catabolic muscle effects. Among the best-characterized GHRPs in the literature. Commonly paired with CJC-1295 (no DAC) or Sermorelin for synergistic GH axis support.
What Is GHRP-2?
GHRP-2 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide and one of the most extensively studied growth hormone releasing peptides (GHRPs), with human pharmacokinetic data, pediatric short-stature trials, and adult studies on GH pulsatility, appetite, and anti-catabolic effects. It acts as a potent agonist at the GHS-R1a ghrelin receptor, stimulating robust short-burst GH release from pituitary somatotrophs while suppressing somatostatin tone. GHRP-2 has a short plasma half-life of approximately 30–40 minutes with a GH pulse peaking around 20–40 minutes post-injection, making it well-suited for pulsatile GH protocols. It is commonly paired with GHRH analogs such as CJC-1295 (no DAC) or Sermorelin for synergistic GH axis support.
Key Benefits
- Potent, short-burst GH release via GHS-R1a agonism — GH peak within ~25 minutes post-injection, fully cleared within a few hours
- Synergistic with GHRH analogs (CJC-1295 no DAC, Sermorelin) — dual-pathway activation produces substantially larger GH pulses than either peptide alone
- Anti-catabolic in skeletal muscle — directly attenuates Atrogin-1 and MuRF1 ubiquitin ligase expression, reducing proteolysis in catabolic states
- Orexigenic signaling via ghrelin receptor — increases food intake, making it a research tool for appetite regulation and cachexia models
- Among the best-characterized GHRPs in published human pharmacokinetic literature
Mechanism of Action
GHRP-2 binds GHS-R1a at both the pituitary (amplifying GH release from somatotrophs and dampening somatostatin tone) and hypothalamus (influencing appetite and energy balance via ghrelin-responsive neurons). Downstream pituitary effects drive increased GH secretion with subsequent IGF-1 elevation after repeated pulses. In peripheral skeletal muscle, GHRP-2 acts via ghrelin receptors to reduce Atrogin-1 and MuRF1 mRNA expression — the muscle-specific ubiquitin ligases responsible for proteolysis in catabolic states — while stimulating protein synthesis pathways. Notably, GHRP-2 does not significantly alter myostatin mRNA expression, distinguishing its anti-catabolic mechanism from myostatin inhibitors. Short plasma half-life (~33 min IV in pediatric PK study) means each injection creates a discrete, rapid GH pulse rather than sustained elevation.
Research Indications
GH Axis & Body Composition
Models GH pulsatility restoration for age-related GH decline. Repeated pulses drive IGF-1 elevation over weeks, especially when paired with a GHRH analog. Animal and swine studies show improved growth performance and protein deposition; human body composition data are more modest and primarily endocrine-oriented.
Appetite & Metabolic Research
Human trials confirm GHRP-2 significantly increases food intake via GHS-R1a, mirroring endogenous ghrelin. Used to dissect orexigenic pathways, study GHS-R1a-mediated appetite signaling, and explore quality-of-life improvements in cachectic populations.
Anti-Catabolic & Cachexia Models
Myocyte studies show reduction of Atrogin-1/MuRF1 expression, limiting proteolysis and supporting protein synthesis. A systematic review notes potential benefits in cancer cachexia and wasting conditions with improved appetite and possible survival signals in some models.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| GH Pulsatility / Anti-Aging | 100 mcg | 2x daily (morning, bedtime) | SubQ |
| Body Composition / Recovery | 100–150 mcg | 3x daily (morning, pre-workout, bedtime) | SubQ |
| Maximum GH Pulse (with GHRH analog) | 150–200 mcg | 2–3x daily with CJC-1295 no DAC or Sermorelin | SubQ |
| Anti-Catabolic Muscle Research | 100–200 mcg | 2–3x daily in pilot contexts | SubQ |
| Appetite / Orexigenic Studies | 1 mcg/kg | Single bolus in controlled setting | IV |
Timing
Administer fasted — morning, pre-workout, or 30–60 minutes before bed. Elevated insulin and glucose from meals blunt the GH response; low-insulin windows are essential. GH elevation begins within ~30 minutes post-injection and clears within 1–2 hours. IGF-1 rises measurably after 2–4 weeks of consistent pulses. Body composition changes require 6–12 weeks with consistent training and nutrition. Cycle 8–12 weeks then allow 4+ weeks off for GH/IGF-1 normalization and receptor sensitivity recovery.
Peptide Interactions
GHRH analog primes somatotrophs; GHRP-2 suppresses somatostatin and activates ghrelin receptor, producing substantially larger GH pulses than either peptide alone. The most common and well-supported pairing in GH-axis research.
Same receptor class; GHRP-6 typically produces stronger appetite stimulation. Combining the two is generally redundant and may over-amplify GH-ghrelin activity without meaningful additional benefit.
More potent GHRP acting at the same receptor. Combined use can lead to excessive GH/IGF-1 elevation and accelerated GHS-R1a desensitization. Avoid unless specifically studying additive effects.
MK-677 provides continuous GHS-R1a stimulation 24 hours a day. Adding pulsatile GHRP-2 on top of a chronic signal risks receptor saturation, elevated IGF-1, and increased side effects (insulin resistance, water retention).
Elevated insulin and glucose significantly blunt the GH response to GHRP-2. Administer in a fasted or low-insulin state to maximize pulse amplitude.
Some studies specifically explore GHRP-2 ability to counter glucocorticoid-induced muscle wasting via its anti-catabolic Atrogin-1/MuRF1 mechanism, representing a distinct therapeutic research direction.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Short half-life (~33 min) means the peptide clears within hours — fasted administration is essential to prevent insulin-mediated blunting of GH release
Appetite increase is confirmed in human trials; beneficial in wasting states but counterproductive for weight management goals
Transient flushing or warmth shortly after injection is common and typically resolves within 30–60 minutes
Mild transient changes in blood glucose and insulin sensitivity noted; relevant for individuals with diabetes or metabolic syndrome
Long-term effects of chronic GH secretagogue use on cardiovascular remodeling are not fully characterized; do not use indefinitely without medical oversight
Do Not Use If:
Active malignancy — any GH/IGF-1 enhancing agent is generally contraindicated due to potential growth-promoting environment
Diabetes or significant insulin resistance without active glucose monitoring and medical supervision
Significant cardiovascular disease until long-term secretagogue safety data are available
Seek Medical Attention If:
Sudden or severe hypoglycemia symptoms (shakiness, confusion, cold sweat)
Significant or persistent fluid retention or pitting edema
Unexpected cortisol or prolactin-related symptoms
Always consult a licensed physician before and during use
Quality Indicators
Verified
Certificate of Analysis (CoA)
HPLC purity of 98% or greater, mass spectrometry identity confirmed, and absence of significant impurities. Critical given the potency of GH-releasing peptides at microgram doses.
Verified
Lyophilized powder appearance
White to off-white lyophilized cake or powder. Discoloration (yellow or brown) or visible debris indicates potential degradation or contamination.
Verified
Clear solution on reconstitution
Reconstituted with bacteriostatic water, solution should be clear and colorless. Cloudiness or particulate matter signals degradation.
Caution
Storage and stability
Lyophilized: stable approximately 2 years refrigerated and protected from light. Reconstituted: use within 30 days refrigerated. Stability drops sharply at room temperature or with repeated freeze-thaw cycles.
CAUTION — NOT RECOMMENDED
Pre-mixed ready-to-inject solutions
Pre-mixed GHRP-2 with unknown storage history carries high degradation risk. Only source lyophilized powder and reconstitute yourself with fresh bacteriostatic water.
Reported Research Timeline
01Day 1–7 (reported in cited studies): short-duration GH pulses after each injection; some subjects experience mild warmth or flushing within 30 minutes. Increased hunger akin to ghrelin effect is common, particularly at higher doses.
02Week 2–4 (reported in cited studies): improved workout recovery and reduced DOMS; modest improvements in sleep quality; IGF-1 begins to trend upward on lab testing with consistent twice or three-times daily dosing.
03Week 4–8 (reported in cited studies): subtle body composition shifts in conjunction with diet and training — slightly leaner with improved muscle fullness; possible improvements in skin texture and joint comfort.
04Week 8–12 (reported in cited studies): more sustained body composition and performance changes in responders; appetite modulation remains present throughout. Monitor GH, IGF-1, and metabolic markers; consider dose adjustment based on lab results.
05Post-cycle: GH and IGF-1 normalize within days of stopping; appetite returns toward baseline. Anabolic and anti-catabolic gains largely reflect training and nutrition quality during the cycle rather than peptide alone.
Research Citations
Research Focus
GH Pulsatility, Anti-Catabolic, Appetite Modulation, Body Composition
Verified Vendors Carrying GHRP-2
Frequently Asked Questions
What should researchers watch for with GHRP-2?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with GHRP-2?
Day 1–7 (reported in cited studies): short-duration GH pulses after each injection; some subjects experience mild warmth or flushing within 30 minutes. Increased hunger akin to ghrelin effect is common, particularly at higher doses.
How is GHRP-2 typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →